Stevanato Group, a leading provider of drug containment and delivery solutions, reported strong financial results for the fourth quarter and fiscal year 2024, driven by robust demand for its high-value solutions and ongoing capacity expansions.

In the fourth quarter, the company's revenue rose 3% year-over-year to €330.6 million, surpassing analyst expectations of €322.1 million. The growth was fueled by a 7% increase in the company's Biopharmaceutical and Diagnostic Solutions (BDS) segment, offsetting a decline in its Engineering segment. Adjusted earnings per share (EPS) for the quarter stood at €0.19, beating estimates of €0.18.

For the full fiscal year 2024, Stevanato Group reported revenue of €1,104 million, up 2% from the previous year, with high-value solutions accounting for 38% of total revenue. The company's adjusted EPS for the year was €0.48.

Looking ahead, the company is introducing its fiscal year 2025 guidance, expecting continued growth driven by solid demand for high-value solutions and the benefits of its ongoing capacity expansion projects. Stevanato Group forecasts revenue in the range of €1,160 million to €1,190 million, adjusted EBITDA between €293.0 million and €306.3 million, and adjusted EPS of €0.51 to €0.55.

Franco Stevanato, Chairman and Chief Executive Officer, commented, "We continue to deliver organic growth driven by solid demand for high-value solutions, and we expect to increasingly benefit from our ongoing capacity expansion projects as they continue to scale and mature. We enjoy an enviable market position, and our unique value proposition makes us a partner of choice for customers. Above all, we are committed to putting the business on the right path to return to double-digit growth, expand margins, and build long-term shareholder value."